About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Eurasian Hematology-Oncology Group
http://www.ehog.net/
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Leukemia
Lymphoma
Myeloma
MDS and MPN
Benign Hematology
Videos
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
Leukemia
Lymphoma
Myeloma
MDS and MPN
Benign Hematology
Videos
8th Eurasian Hematology Oncology Summit
XIth Eurasian Hematology-Oncology Congress - EHOC 2020
Palliative & Supportive Care
COVID-19
Basic Science
Leukemia
Lymphoma
Myeloma
MDS and MPN
Benign Hematology
Lung
Business
7th Eurasian Hematology Oncology Summit
COVID-19
Leukemia
Lymphoma
Myeloma
MDS and MPN
Xth Eurasian Hematology-Oncology Congress
Breast
Lung
Hematologic Oncology
Gastrointestinal
Genitourinary
General Oncology
Sarcoma
Skin
Head & Neck
Events
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
Debates in Ph+ ALL: Allo-SCT Is Not Necessary Upfront in Adult Patients
By
XV Eurasian Hematology-Oncology Congress - EHOC 2024
FEATURING
Elias Jabbour
By
XV Eurasian Hematology-Oncology Congress - EHOC 2024
FEATURING
Elias Jabbour
16 views
September 6, 2024
0 Comments
Login to view comments.
Click here to Login
Featured Video
11:12
Stemline
A proven CD123 targeted therapy for BPDCN
Feat.
H. Erba
Featured Video
16:26
Incyte
Effects of a Treatment Option on Hematocrit Control and Spleen Volum…
Feat.
C. Harrison
Leukemia
07:49
XV Eurasian Hematology-Oncology Congress - EHOC 2024
A Case of CMML With Recurrent Skin Involvement
Feat.
E. Arslan Davulcu
15:14
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Critical Re-Evaluation of Established Practices in CML Management
Feat.
H. Kantarjian
28:43
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Management of R/R AML: Treatment Options and Case Insights
Feat.
V. Bonuomo
19:01
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Debates in AML: 7+3 Is No Longer the Standard of Care
Feat.
T. Kadia
14:17
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Practical Approach to MRD Monitoring in AML: Assessing Treatment Eff…
Feat.
T. Kadia
10:30
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Debates in Ph+ ALL: Allo-SCT Should Be Used Upfront in Adult Patients
Feat.
D. Hoelzer
09:06
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Debates in Ph+ ALL: Allo-SCT Is Not Necessary Upfront in Adult Patie…
Feat.
E. Jabbour
23:52
XV Eurasian Hematology-Oncology Congress - EHOC 2024
CLL Case Discussion: First Line Treatment Strategies
Feat.
D. Ortaboz
18:01
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Incorporation of Targeted and Immunotherapies in ALL
Feat.
H. Kantarjian
18:49
XV Eurasian Hematology-Oncology Congress - EHOC 2024
CAR-T in R/R ALL: Case-Based Discussion of Lymphodepletion and Toxic…
Feat.
E. Erdogan
17:13
XV Eurasian Hematology-Oncology Congress - EHOC 2024
The Importance of MRD in ALL
Feat.
F. Ravandi
22:26
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Management of AML in Older Patients
Feat.
F. Ravandi
34:29
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Current Approaches to Managing T-Cell ALL
Feat.
A. Ibrahim
15:10
XV Eurasian Hematology-Oncology Congress - EHOC 2024
TKI Toxicity Management in CML: A Case-Based Discussion
Feat.
A. Alshurafa
18:56
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Management of Persistently MRD+ ALL
Feat.
A. Odabasi Giden
18:07
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Debates in AML: 3+7 is the SOC Induction Therapy for AML
Feat.
A. Uzay
11:33
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Venetoclax + Ibrutinib as 1L Treatment in Patients With CLL: Meta-An…
Feat.
A. Sarici
16:19
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Current Options for Finite-Duration Therapy With BTKis in CLL
Feat.
A. Ibrahim
